FDA approves first DNA-based treatment for a rare airway disease
Published
Inovio's Voceryq won accelerated approval for adults with recurrent respiratory papillomatosis, where noncancerous growths in the airway keep coming back and require repeated surgeries. It's given as shots over nine weeks with a special device. In a small study, about a quarter of patients needed no surgery for a year. A follow-up trial may be required.
Source: HCPLive
This is a plain-language summary. Read the original source for full details.